Foresite Capital Management IV’s Aclaris Therapeutics ACRS Stock Holding History

Foresite Capital Management IV’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,808,034	Closed	-$19.2M	–	6
2023 Q3	$19.2M	Hold	2,808,034	–	–	10.68%	3
2023 Q2	$29.1M	Hold	2,808,034	–	–	14.32%	4
2023 Q1	$22.7M	Hold	2,808,034	–	–	11.79%	4
2022 Q4	$44.2M	Hold	2,808,034	–	–	18.89%	2
2022 Q3	$44.2M	Hold	2,808,034	–	–	14.21%	3
2022 Q2	$39.2M	Sell	2,808,034 -91,000	-3%	-$1.28M	10.56%	4
2022 Q1	$50M	Sell	2,899,034 -500,000	-15%	-$6.82M	13.98%	4
2021 Q4	$49.4M	Hold	3,399,034	–	–	10.17%	3
2021 Q3	$61.2M	Hold	3,399,034	–	–	9.01%	3
2021 Q2	$59.7M	Hold	3,399,034	–	–	8.07%	4
2021 Q1	$85.7M	Buy	3,399,034 +2,447,650	+257%	+$47.9M	10.26%	3
2020 Q4	$6.16M	Buy	951,384 +806,510	+557%	+$3.4M	0.67%	12
2020 Q3	$372K	Buy	+144,874	New	+$324K	0.08%	15
2019 Q1	–	Sell	-748,132	Closed	-$5.53M	–	17
2018 Q4	$5.53M	Buy	748,132 +218,581	+41%	+$2.25M	2.54%	14
2018 Q3	$7.69M	Hold	529,551	–	–	2.52%	13
2018 Q2	$10.6M	Buy	529,551 +100,000	+23%	+$1.85M	3.6%	11
2018 Q1	$7.53M	Buy	429,551 +177,615	+71%	+$3.76M	3.12%	12
2017 Q4	$6.21M	Buy	+251,936	New	+$6.13M	4.36%	8

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Foresite Capital Management IV's ACRS Position: Q4 2023 in Review

Foresite Capital Management IV sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 2,808,034 shares — an estimated $19.2M sold.

Foresite Capital Management IV first reported a position in ACRS in Q4 2017 and held it in 18 quarters. The position peaked at $85.7M in Q1 2021. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Foresite Capital Management IV reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Foresite Capital Management IV sold 2,808,034 Aclaris Therapeutics shares in Q4 2023, an estimated $19.2M.
Foresite Capital Management IV first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 18 quarters.
Foresite Capital Management IV's Aclaris Therapeutics position peaked at $85.7M in Q1 2021.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Foresite Capital Management IV's 13F filing for Q4 2023, filed 13 Feb 2024.